Honeywell (HON) stock rose 1.7% in December 2016. The company’s stock performance in December was muted compared to November’s returns of 3.9%.
On January 6, 2017, Axalta (AXTA) announced that it had acquired Ellis Paint Company. Axalta didn’t disclose the financial terms of the deal.
On January 5, 2017, PPG Industries (PPG) announced that it had completed the acquisition of DEUTEK, a leading Romanian paint and architectural coatings manufacturer.
On January 4, 2017, Albemarle (ALB) announced that it had issued a tender offer to repurchase debt worth $500 million.
As of January 4, 2017, Dow Chemical (DOW) was trading at a one-year forward PE multiple of 14.3x.
As of January 4, 2017, 20 brokerage firms were actively tracking Dow Chemical stock. Of these analysts, 75.0% have recommended a “buy” for the stock.
The Fed’s rate hike in December 2016 is expected to benefit DOW’s pension plan in fiscal 2017 because a higher discount rate will be applied to calculate PBO.
Dow Chemical (DOW) stock continued its upward trend in December, rising 2.7% after a 3.6% rise in November.
On December 29, 2016, BDX stock was trading 28.3% above its 52-week low of $129.50 on February 9, 2016, and 5% below its 52-week high of $181.70 on September 22, 2016.
Becton, Dickinson and Company (BDX), expects its 2017 sales to be hit due to the divestiture of its Respiratory Solutions business, which was completed in October 2016.
BDX expects to generate operating cash flows of more than $11 billion for the five-year period from 2016 to 2019.
BDX’s R&D investments totaled ~$828 million in fiscal 2016, which represents an annual growth of ~31%.
The BD Medical business generated revenues of ~$8.7 billion in fiscal 2016, which ended September 30, 2016.
Becton, Dickinson and Company (BDX) generates ~$1 billion from its Infection Prevention business.
Becton, Dickinson and Company (BDX) recently launched BD Barricor and BD Ultra Touch Push Button under its Pre-Analytical Systems division.
St. Jude Medical (STJ) announced a fiscal 4Q16 cash dividend of $0.31 per share on December 9, 2016.
St. Jude Medical (STJ) is trading at $79.83 as of December 29, 2016, and has a 50-day moving average of $79.69 and a 200-day moving average of $79.75.
On December 8, 2016, St. Jude Medical (STJ) announced CE Mark approval for full body MR (magnetic resonance) conditional labeling for the Proclaim Elite SCS (spinal cord stimulation) System.
The FTC (Federal Trade Commission) has approved the $25 billion acquisition of St. Jude Medical (STJ) by Abbott Laboratories (ABT) subject to certain conditions.
Praxair shares dropped 4.0% for the week ended December 23, 2016, and closed at $117.59, as many analysts believed that the proposed merger is more favorable to Linde shareholders.